Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion of the latter’s innovative oral therapeutic candidates. This acquisition, made in an all-cash transaction, will incorporate DICE Therapeutics’ breakthrough DELSCAPE technology platform, designed for developing advanced oral therapeutic candidates. Specifically, […]
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, and Taltz. The revenue spike includes a notable $579.0 million from the Baqsimi rights sale. Excluding this sale and 2022’s COVID-19 antibodies, the Q2 2023 revenue surged by 22%. Key […]
Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. DICE Therapeutics has developed the DELSCAPE technology platform for developing novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to address chronic diseases in immunology. Patrik Jonsson […]
